Intellipharmaceutics International Inc. Quarterly Operating Income (Loss) in USD from Q2 2017 to Q3 2023

Taxonomy & unit
us-gaap: CAD and USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Intellipharmaceutics International Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q3 2023.
  • Intellipharmaceutics International Inc. Operating Income (Loss) for the quarter ending August 31, 2023 was -$1.79M, a 388% decline year-over-year.
  • Intellipharmaceutics International Inc. Operating Income (Loss) for the twelve months ending August 31, 2023 was -$2.58M, a 31.9% increase year-over-year.
  • Intellipharmaceutics International Inc. annual Operating Income (Loss) for 2022 was -$2.85M, a 31.7% increase from 2021.
  • Intellipharmaceutics International Inc. annual Operating Income (Loss) for 2021 was -$4.17M, a 10.8% increase from 2020.
  • Intellipharmaceutics International Inc. annual Operating Income (Loss) for 2020 was -$4.68M, a 40.3% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$2.58M -$1.79M -$1.42M -388% Jun 1, 2023 Aug 31, 2023 6-K 2023-10-16
Q2 2023 -$1.16M -$31.4K +$1.22M +97.5% Mar 1, 2023 May 31, 2023 6-K 2023-09-26
Q1 2023 -$2.38M -$301K +$472K +61% Dec 1, 2022 Feb 28, 2023 6-K 2023-09-26
Q4 2022 -$2.85M -$460K +$938K +67.1% Sep 1, 2022 Nov 30, 2022 20-F/A 2024-02-06
Q3 2022 -$3.79M -$366K +$718K +66.2% Jun 1, 2022 Aug 31, 2022 6-K 2023-10-16
Q2 2022 -$4.51M -$1.25M -$345K -38% Mar 1, 2022 May 31, 2022 6-K 2023-09-26
Q1 2022 -$4.16M -$773K +$12K +1.53% Dec 1, 2021 Feb 28, 2022 6-K 2023-09-26
Q4 2021 -$4.17M -$1.4M +$64.9K +4.44% Sep 1, 2021 Nov 30, 2021 20-F/A 2024-02-06
Q3 2021 -$4.24M -$1.08M +$45.6K +4.04% Jun 1, 2021 Aug 31, 2021 6-K 2022-10-14
Q2 2021 -$4.28M -$907K -$16.6K -1.87% Mar 1, 2021 May 31, 2021 6-K 2022-07-21
Q1 2021 -$4.27M -$785K +$411K +34.4% Dec 1, 2020 Feb 28, 2021 6-K 2022-04-14
Q4 2020 -$4.68M -$1.46M -$185K -14.5% Sep 1, 2020 Nov 30, 2020 20-F/A 2024-02-06
Q3 2020 -$4.49M -$1.13M +$231K +17% Jun 1, 2020 Aug 31, 2020 6-K 2021-10-15
Q2 2020 -$4.72M -$890K +$1.15M +56.4% Mar 1, 2020 May 31, 2020 6-K 2021-07-15
Q1 2020 -$5.88M -$1.2M +$1.96M +62.1% Dec 1, 2019 Feb 29, 2020 6-K 2021-04-14
Q4 2019 -$7.83M -$1.28M +$2.25M +63.8% Sep 1, 2019 Nov 30, 2019 20-F/A 2022-05-09
Q3 2019 -$10.1M -$1.36M +$2.54M +65.2% Jun 1, 2019 Aug 31, 2019 6-K 2020-10-15
Q2 2019 -$12.6M -$2.04M +$762K +27.2% Mar 1, 2019 May 31, 2019 6-K 2020-07-15
Q1 2019 -$13.4M -$3.15M -$63.1K -2.04% Dec 1, 2018 Feb 28, 2019 6-K 2020-05-29
Q4 2018 -$13.3M -$3.53M Sep 1, 2018 Nov 30, 2018 20-F 2021-03-31
Q3 2018 -$3.9M -$1.54M -64.8% Jun 1, 2018 Aug 31, 2018 6-K 2019-10-11
Q2 2018 -$2.81M -$1.05M -60.3% Mar 1, 2018 May 31, 2018 6-K 2019-07-10
Q1 2018 -$3.09M Dec 1, 2017 Feb 28, 2018 6-K 2019-04-15
Q3 2017 -$2.37M Jun 1, 2017 Aug 31, 2017 6-K 2018-10-15
Q2 2017 -$1.75M Mar 1, 2017 May 31, 2017 6-K/A 2018-07-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.